home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2807.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
47 lines
Document 2807
DOCN M94A2807
TI Efficacy of interferon for chronic hepatitis C in HIV+ patients.
HIV/IFN/HCV Spanish Study Group.
DT 9412
AU Soriano V; Garcia-Samaniego J; Bravo R; Castro A; Gonzalez J;
Mtnez-Odriozola P; Colmenero J; Carballo E; Del Romero J; Pedreira J; et
al
SO Int Conf AIDS. 1994 Aug 7-12;10(1):220 (abstract no. PB0310). Unique
Identifier : AIDSLINE ICA10/94369768
AB OBJECTIVE: To determine the efficacy and safety of rIFN therapy for CHC
in HIV+ individuals. PATIENTS: 88 HIV+ patients fulfilling clinical and
histological criteria for CHC and 27 HIV-negative subjects (controls)
suffering CHC. METHODS: rIFN alfa-2b (Intron) 5 megaU was given 3 days a
week subcutaneously during 3 months. In responding patients, rIFN 3
megaU 3 times a week was administered during additional 9 months.
RESULTS: Among 72 HIV+ patients, 31 (43%) achieved complete response
(CR). Mean follow-up was 36 weeks (range 18 to 98). Patients with CD4+
cells above 500/mm3 achieved CR in 53% (18 out of 34) of cases compared
to 34% (13 out of 38) among those with lower CD4+ count (p < 0.01).
Interestingly, 64% of women but only 34% of men (p < 0.01) allowed CR,
and this difference remained in multivariate analysis. No serious side
effects or opportunistic infections were observed during the study
period. However, 4 (6%) HIV+ patients showed a dramatic fall in total
CD4+ T cell count after began IFN therapy. Mean pre-treatment ALT levels
were not significantly lower among responders (x = 187) compared to
non-responders (x = 224). Among 27 HIV-negative patients, CR was
achieved in 14 (52%). Initial mean ALT levels among responders were
significantly lower (x = 98) compared to partial or non-responders (x =
146) (p < 0.05). CONCLUSIONS: rIFN therapy seems to be well tolerated
and useful in HIV+ patients suffering CHC. However, healing is lower
(34% versus 53%) in subjects with less than 500 CD4+ cells/mm3 (p <
0.01). Furthermore, women achieved CR more frequently than men. Effect
of IFN therapy on CD4+ T cells needs to be clarified in these patients.
DE Alanine Aminotransferase/BLOOD Biological Markers/BLOOD Biological
Response Modifiers/ADVERSE EFFECTS/PHARMACOLOGY/ *THERAPEUTIC USE
Comparative Study Drug Evaluation Female Hepatitis
C/COMPLICATIONS/ENZYMOLOGY/*THERAPY Hepatitis, Chronic
Active/COMPLICATIONS/ENZYMOLOGY/*THERAPY Human HIV
Infections/*COMPLICATIONS Interferon Alfa-2b/ADVERSE
EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Leukocyte Count/DRUG EFFECTS
Male Treatment Outcome T4 Lymphocytes MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).